ImpriMed, a precision medicine company, is expanding its services to include human oncology, focusing on drug-response predictions for routine blood cancers like multiple myeloma and acute myeloid leukemia. They will use genomic analysis, ex vivo drug sensitivity testing, and machine learning to target complex blood cancers. Data from new research on non-Hodgkin lymphoma treatment outcomes will be presented at a meeting in Copenhagen. The CEO, Dr. Sungwon Lim, believes this expansion will transform cancer treatment by providing personalized therapy through AI-driven technology. ImpriMed also recently published research on a novel cell-sizing method for feline lymphomas and launched an AI service for canine patients with lymphoma or leukemia.
Source link
ImpriMed unveils cancer treatment forecast technology
